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Transplant arteriosclerosis and in-stent 
restenosis: (dis)similarities in pathogenesis 
and treatment perspectives








EPC endothelial progenitor cell
ECM extracellular matrix
ISR         in-stent restenosis
NI neointima
SMPC smooth muscle progenitor cell
TA transplant arteriosclerosis
VSMC  vascular smooth muscle cell
Abstract
Vascular remodeling is a broadly used term which describes structural changes of the 
arterial wall as a response to various stimuli resulting in the narrowing of the vessel lumen 
and subsequent downstream tissue ischemia. Transplant Arteriosclerosis (TA) and in-stent 
restenosis (ISR) are two major vascular diseases characterized by obliterative vascular 
remodeling and may be regarded as healing processes within the vascular wall that, 
however, proceed beyond the needs of functional repair leading to a vascular maladaptive 
status. The common hallmark of these obliterative vascular diseases is intimal thickening 
resulting from both an increase in the number of cells in the subendothelial intima (i.e. 
vascular smooth muscle cell proliferation) as well as the amount of extracellular matrix 
proteins, culminating in neointima (NI) formation. Various insults to the vascular bed 
result in endothelial injury which constitutes the initiating stimuli resulting in luminal 
narrowing and impaired vascular function. As yet, no adequate preventive or curative 
therapies are available to prevent NI formation in TA and ISR. This General Introduction 
focuses on the cellular and molecular mechanisms involved in NI formation in TA and ISR. 
Although these diseases present many similarities, they represent distinct forms of vascular 
remodeling processes. Similarities and differences between the underlying pathogenetic 
mechanisms are being discussed and potential treatment strategies are being presented. 
Particular emphasis is given to endothelial and smooth muscle vascular progenitor cells 




Vascular remodeling and neointima formation 
Vascular remodeling is a broadly used term which describes structural changes of the arterial 
wall as a response to various stimuli, such as wall shear stress, hypoxia, and immunological 
or mechanical injuries, that lead to changes in vessel size and luminal width.1 The complex 
set of vascular changes includes altered phenotype and localization as well as function of 
endothelial cells (ECs) and vascular smooth muscle cells (VSMCs). This coincides with 
changes in extracellular matrix (ECM) composition.2 Vascular remodeling is an active 
process of structural modification in which at least four cellular processes are involved: cell 
proliferation, cell death, cell migration, and production or degradation of ECM. Vascular 
remodeling is dependent on a dynamic interaction between locally generated growth factors, 
vasoactive substances, and hemodynamic stimuli.3 Narrowing, thickening and stiffening (i.e. 
loss of elasticity) of the vessel wall will result in reduced blood flow and subsequent ischemia 
in downstream tissue/organs. Vascular remodeling has various clinical and pathological 
manifestations, including spontaneous (native) atherosclerosis, transplant arteriosclerosis 
(TA), arterial bypass graft atherosclerosis, vein graft stenosis, restenosis after percutaneous 
transluminal coronary angioplasty, and in-stent restenosis (ISR). The common hallmark of 
these obliterative vascular pathologies is intimal thickening resulting from both an increase 
in the number of cells in the subendothelial intima as well as the amount of ECM.4 As 
yet, no adequate preventive or curative therapies are available to treat NI formation in TA 
and ISR. The NI consists of VSMCs, ECM and inflammatory cells5 forming a fibrotic layer 
covered at the luminal side by endothelium. In all these inflammatory, proliferative, and 
migratory events a primary (common) pathophysiologic mechanism supposedly underlies 
uncontrolled VSMC proliferation as observed in TA and ISR.6 
Both TA and ISR develop as a result of the interventions performed, in part, to treat 
occlusive atherosclerotic diseases and end-stage organ dysfunction due to ischemic damage. 
TA and ISR may be regarded as healing processes within the vascular wall that, however, 
proceed beyond the needs of functional repair leading to a vascular maladaptive status. 
We propose that damage of the tissue architecture elicits an evolving defense reparative 
mechanism aiming for vascular wall re-building. The presence of ongoing perivascular 
inflammation will however sabotage the initial defense mechanism resulting in excessive 
pathological repair culminating in vessel obstruction, downstream ischemic tissue damage, 
and tissue necrosis.
This General Introduction focuses on the cellular and molecular mechanisms involved 
in NI formation in TA and ISR. Similarities and differences between the underlying 
pathogenetic mechanisms are being discussed and potential targets for therapeutic 
intervention are being presented. Particular emphasis is given to endothelial and smooth 
muscle vascular progenitor cells and their role in vessel homeostasis as well as their 




Progenitor cells in vascular remodeling
During vascular remodeling processes both ECs and VSMCs are actively involved. 
Maintenance of vascular endothelial integrity and repair was historically believed to be 
regulated exclusively by resident mature vascular cells. However, it is now recognized 
that populations of vascular progenitor cells in a variety of tissues which are capable of 
differentiation into ECs and VSMCs, thereby participating in neointima formation and 
vascular remodeling.7 Vascular progenitor cells include both endothelial progenitor cells 
(EPCs) and smooth muscle progenitor cells (SMPCs). Vascular progenitor cells have been 
identified in the BM, in the circulation, in the vessel wall, and in various extravascular sites 
(Figure 1).8 The BM contains hematopoietic and mesenchymal stem cells which have the 
ability of self-renewal and differentiation into a variety of cell types including VSMCs.9-11 
Similarly, human peripheral blood monocyte-derived subsets act as pluripotent stem cells 
and can be induced to acquire macrophage, epithelial, endothelial, neuronal, and hepatocyte 
phenotypes.12 Vascular progenitor cells that can differentiate in culture into either 
endothelial or smooth muscle cells have been isolated from peripheral human blood.13,14 
Besides circulating progenitor cells, vascular wall progenitor cells have been identified in 
so-called vasculogenic zones in the media15 as well as in the adventitia16,17 in rodent and 
human arteries. The vascular progenitor cells in tunica media of healthy adult mice were 
Sca-1+, c-kitlow and CD34low, and were able to undergo EC and VSMC differentiation when 
exposed to VEGF and TGB-β1/PDGF-BB, respectively.15 Similarly, vascular progenitor 
cells residing in the mouse aorta adventitia express Sca-1 and differentiate in vitro into 
ECs and VSMCs when exposed to VEGF-A and PDGF-BB, respectively.17 In human vessels 
a population of CD31-CD34+ cells has been identified at the border of the media and 
adventitia of large- and medium-sized arteries and veins.16,18,19 Within the vascular wall, 
the adventitia is not considered anymore as just a layer of connective tissue supporting 
the blood vessel, but rather as an active participant in vascular progenitor cell transfer by 
providing progenitor cell niches and contribution to the movement of these cells between 
BM, circulation and vessel wall.20 Another location for vascular wall progenitor cells, which 
has been reported with pericytic properties, is the subendothelial zone.21 Based on these 
data, there is evidence for the existence of BM-derived recirculating and resident vascular 
wall progenitor cells, with a direct and indirect role, due to paracrine mechanisms, in 
vascular remodeling. It is still unknown whether EPCs and SMPCs are derived from a 
common ancestral vascular progenitor cell which then may have a dichotomous role in its 
response to vascular injury: a beneficial role for endothelial repair (EPC) and a detrimental 
role in neointima formation (SMPC).22-24 Identification of the exact phenotype of these 
(recirculating) cells as well as the molecular mechanisms that drive their differentiation 
is a prerequisite in developing efficacious future strategies aiming at modulating vascular 





Chronic transplant dysfunction and transplant arteriosclerosis
Cardiac transplantation is a widely accepted therapy for the treatment of end-stage 
congestive heart failure (mostly ischemic and dilated cardiomyopathy). Candidates for 
cardiac transplantation are patients that are refractory to conventional medical therapy and 
are excluded from other surgical interventions because of the poor condition of the heart.25 
Current immuno sup pres sive therapy, of which the mainstay is provided by calcineurin 
inhibitors (CsA, FK506), is effective to treat acute rejection but not to prevent cardiac 
allograft vasculopathy which is also referred to as transplant arteriosclerosis (TA). Therapy 
for TA has thus been disappointing and the only definitive treatment is retransplantation 
since intragraft revascularization therapy does not result in survival benefit. To date, TA 
Figure 1. Possible sources of vascular progenitor cells. Vascular progenitor cells have been identified in the bone 
marrow, in the circulation, in the vessel wall, and in various extravascular sites. There is most likely a continuous 
movement of cells between the different compartments via the circulation. The lower panel displays a schematic 
representation of (a part) a cross-section of and artery and shows the different layers of the vessel wall in which the 
so far identified stem cell niches (such as the “vasculogenic zone” in the adventitia and the sub-endothelial space) 




is the main cause of Chronic Transplant Dysfunction (CTD) and thereby the main factor 
limiting the long-term success of cardiac transplan tation. TA is the second leading cause 
of death after 1 year following transplantation, second only to malignancy.26 TA occurs in 
>50% of heart transplant recipients in the first several years after transplantation.27 TA is 
characterized by concentric neointimal proliferation with lumen narrowing and ischemic 
tissue damage with loss of graft function eventually. 
Both alloantigen-dependent and independent factors are described as risk factors for 
TA development.28,29 Alloantigen-dependent factors include the number of donor-recipient 
HLA mismatches and the number, duration and time of onset of rejection episodes.30,31 
Alloantigen-independent risk factors include hyperlipidemia, older donor age, obesity, 
diabetes mellitus, hypertension, hyperhomocysteinemia, cytomegalovirus infection, 
ischemia/reperfusion injury, and donor brain death.28,30-34
Endothelial and medial smooth muscle cell injury in TA development
The first line of contact between the transplanted donor organ and recipient blood is 
the graft endothelium. Allogenic graft ECs serve as potent stimuli of the alloimmune 
response and form a major target of alloreactivity. Various immune-mediated pathways 
have indeed been implicated in enhanced EC apoptosis.35 The initial injury to the graft 
endothelium may start even before transplantation primarily due to donor brain death 
and ischemia/reperfusion injury. In TA, non-immune and immune-mediated mechanisms 
initiate apoptosis of ECs, which is then followed by intimal hyperplasia. This sequence 
of events suggests that damage and subsequent apoptosis of ECs play a central role in NI 
formation through the activation of at least three, not mutually exclusive, processes.35 First, 
endothelial apoptosis induces a thrombogenic and hyperadhesive state for inflammatory 
cells, thereby facilitating sustained leukocyte transmigration into the subendothelial 
space resulting in enhanced vascular inflammation which in turn perpetuate the initial 
EC injury.36 Secondly, phagocytosis of apoptotic cells by macrophages increases the 
production of transforming growth factor-β1 (TGF-β1) which is a profibrotic cytokine 
known to increase NI formation.37 Thirdly, EC apoptosis triggers ECM proteolysis thereby 
initiating the production of fibrogenic mediators like TGF-β1, that promote profibrotic 
responses at the sites of injury.35,38 Ongoing EC injury in the graft occurs as the recipients’ 
immune response against donor antigens maintains (i.e. [subclinical] rejection). Damaged 
endothelium will expose the underlying medial VSMCs and ECM to the recirculating 
blood thereby increasing the risk of thrombosis.
It is now well established that the endothelium represents far more than an inert cell layer 
lining the vessel lumen.39 Depending on the type of vascular bed, ECs exert various functions 
including regulation of the vascular tone, coagulation, and inflammatory responses.40 EC 
injury manifests at different levels. Depending on the overall endothelial integrity EC injury 
can be classified as either denuding or non-denuding injury.41 Denuding injury involves the 
loss of a substantial area of endothelial coverage. EC denudation is usually noted during 
significant episodes of acute cellular rejection or vasculitis, as well as during episodes of 




reperfusion.42 The non-denuding form of EC injury does not involve a significant loss of 
endothelial coverage and is characterized by relatively rapid replacement of individual ECs that 
are injured and lost. Clinically, non-denuding EC injury principally presents as endothelial 
dysfunction (i.e. changes in the concentration of the chemical messengers produced by EC 
and/or blunting of the nitric oxide (NO)-dependent vasodilatory response).42,43 Besides 
EC injury of graft endothelium, organ transplantation also has a generalized, systemic 
harmful effect on recipients’ EC function. Systemic EC dysfunction after transplantation 
develops not only as a result of the pre-existent clinical condition (such as diabetes), but 
also develops de novo presumedly as a result of the systemic inflammatory burden caused 
by the ongoing, subclinical rejection response.44 This transplant-associated systemic EC 
dysfunction thus occurs outside the transplanted organ and forms a main contributor to 
the elevated cardiovascular risk that transplant recipients face. Systemic EC dysfunction in 
transplant recipients is associated with significant morbidity and mortality.45-47 The majority 
of renal transplant recipients loose their graft not because of graft failure, but rather due to the 
development of cardiovascular disease resulting in patient death with a functioning graft.48 
Programmed VSMC death plays a significant role in remodeling (including TA) of 
the injured vasculature.35,49-52 Apoptosis of medial VSMCs is triggered by inflammatory 
processes.53-55 The decrease of α-actin expressing medial VSMCs56-60 impairs the graft 
vascular wall architecture and vasomotor function. Vascular injury due to chronic 
inflammation elicits a repair response that involves thrombosis, migration and proliferation 
of vascular cells, matrix production, and infiltration of inflammatory cells (see below).3 
Cytokine-induced activation and proliferation of VSMCs is considered one of the critical 
cellular events in TA development and, accordingly, their proliferation is a potential target 
for therapeutic intervention to attenuate NI formation.61 
Origin of endothelial and smooth muscle cells in TA
The identification of the origin and phenotype of neointimal cells in TA is pivotal in the 
development of therapeutic interventions aiming at targeting VSMCs in the development 
of TA. The response-to-injury hypothesis for the development of atherosclerosis proposes 
medial origin of intraplaque VSMCs.62 For a long time, this hypothesis was also applied to 
the development of TA in allografts. According to this hypothesis, neointimal cells in TA are 
derived from the medial layer of the vascular wall and end up in the subendothelial space 
due to migration.56,63 Arterial VSMCs normally reside in the tunica media in their non-
proliferative contractile state. However, upon injury the release of inflammatory mediators 
results in modulation of the phenotype of donor medial VSMCs, resulting in dedifferentiation 
from a contractile state to a dedifferentiated synthetic cell with proliferative, migratory and 
ECM-secreting capacity.64-67 According to the response-to-injury hypothesis, the VSMCs 
present in the neointima in TA are thus donor-derived. However, in late 90s of the last 
century this hypothesis (holding graft origin of neointimal VSMCs) was challenged and 
there is now, primarily based on data from experimental transplantation in rodents, a well 
documented evidence for (partly) recipient origin of NI cells in TA.22,68-74 Consequently, 




major interest in unraveling the pathogenetic mechanisms underlying TA development. 
Several animal models have been used to study the origin of NI cells in TA including 
solid organ transplants (heart, kidney) as well as arterial (aorta) segments. Depending on 
the experimental transplant model used, different (contradicting) results regarding the 
origin of NI cells in TA were reported. In our laboratory, Hillebrands et al. were able to 
show that neointimal ECs and VSMCs in a rat aorta transplant model were completely of 
recipient origin, whereas in a rat heterotopic cardiac transplant model only the neointimal 
VSMCs turned out to be of recipient origin with preserved graft endothelium.68,75 Using 
a rat kidney transplant model we recently demonstrated that both neointimal ECs and 
VSMCs are of donor origin, whereas ECs in peritubular and glomerular capillaries were 
of both recipient and donor origin.76 Based on our observations and data reported by 
others, we hypothesized that depending on the severity of the initial injury and the donor 
endothelial cell/resident progenitor cell potential to proliferate/differentiate, endothelial 
integrity is restored by either donor resources or by recipient-derived (vascular progenitor) 
cells.5 The differences in data obtained in different models underscores the importance of 
both severity of the injury (in the aorta transplant model recipient ECs and medial VSMCs 
completely disappear with limited remaining capacity for graft-mediated reconstruction) 
and the organ-specific response to injury (i.e. different graft-specific endogenous potential 
to restore the damaged vessel wall). Indeed, Han et al. provided experimental evidence that 
the bone marrow (BM) compartment can serve as complementary source of neointimal 
VSMCs during vascular healing using two types of insult in a murine model: endovascular 
probe scratch injury of the iliac artery and organized arterial thrombus formation into the 
left common carotid artery.77 Using BM chimeric mice, the authors demonstrated that BM-
derived cells contribute to NI formation only when the media of the iliac artery sustained 
severe damage, but not in arteries subjected to minimal medial damage.77 
Various sources of NI VSMCs can thus be identified, including differentiated donor-
derived medial VSMCs15,78, tissue resident donor or recipient-derived vascular progenitor 
cells79,80, transdifferentiation of mature donor ECs into VSMCs (i.e. endothelial-to-
mesenchymal transdifferentiation)81,82, and influx of recipient-derived recirculating BM 
and non-BM-derived stem cells.5,22,69-72,83,84 
In contrast to various experimental studies including our own data68,75, most studies on 
the origin of neointimal VSMCs in TA in human cardiac allografts describe that virtually all 
neointimal VSMCs are donor-derived.85,86 However, in contrast to human cardiac allografts 
Grimm et al. showed that in human renal allografts the majority of neointimal VSMCs 
were of recipient-origin.73 In our laboratory, Boersema et al. also recently determined the 
origin of neointimal ECs and VSMCs in explanted human renal allografts, thereby showing 
that up to 20% of the neointimal VSMCs were recipient-derived.74 Whether organ-specific 
differences might explain the observed differences between the cardiac and renal allografts, 
remains to be elucidated.
Several phenomena might contribute to the differences observed between the 
experimental and clinical studies regarding NI cell origin. First, preserved medial VSMCs 




that can repopulate the neointima. Because in rodent vascular transplantation models 
no or limited (temporarily) immunosuppressive drugs are administered, medial cell 
destruction often leads to (nearly) complete medial VSMC destruction. In contrast, in 
human transplantation more aggressive and prolonged immunosuppressive regimen are 
used to prevent rejection, thereby most likely resulting in protection of complete medial 
VSMC destruction. One can envision that when viable medial VSMCs remain present, 
these cells can serve as a source of NI cells, whereas in the case of complete medial 
destruction, other sources are required by definition. However, in our model of TA in 
cardiac allografts, a small rim of presumably donor-derived medial VSMCs was present, 
whereas virtually all neointimal VSMCs were found to be of recipient origin.68 Another 
difference between experimental rodent models and the human transplant setting might 
be the presence of pre-existing vascular disease (i.e. native atherosclerosis) in the grafts at 
the time of engraftment.87 These intimal lesions contain donor-derived VSMCs that may 
provide the basis for further outgrowth of VSMCs during the subsequent development of 
(posttransplant) TA.85 Such pre-existing intimal lesions are rarely found in animal tissues 
used for transplantation.
Taken together, experimental and human studies show evidence for both recipient- and 
donor- derived VSMCs in NI formation. The pathogenetic mechanisms might depend on 
both the type of transplanted organ as well as the severity and duration of endovascular 
injury.5,76 
Atherosclerosis and (in-stent) restenosis
Atherosclerosis
Atherosclerosis is characterized by asymmetric focal thickening of the arterial tunica 
intima, consisting of VSMCs, inflammatory cells (predominantly T cells and macrophages), 
ECM components, lipids, and necrotic cellular debris.88 Atherosclerosis can affect all large 
and medium-sized arteries and results in luminal narrowing and downstream ischemic 
tissue damage. Atherosclerosis in the coronary arteries is a major cause of heart failure89 
causing high rates of cardiovascular morbidity and mortality.90 A major step forward in the 
treatment of atherosclerosis was the introduction of percutaneous transluminal coronary 
angioplasty (PTCA) in the late 70s.91,92 The main complication following PTCA was, 
however, restenosis development occurring in ~30%-40% of the patients within the first 
6 months after intervention.93 Postangioplasty restenosis results from direct trauma to the 
artery and is believed to represent an arterial healing response after injury.94 Postangioplasty 
restenosis is characterized by vascular elastic recoil, reorganization of thrombi, neointimal 
proliferation and negative remodeling, i.e. reduction in vessel diameter due to inward 
vessel constriction.94-97 This negative remodeling has been significantly improved after the 





Stenting is a method of revascularization of significant obstructive atherosclerosis with 
already a long history in the treatment of coronary artery disease. However, stenting is also 
becoming an increasingly used treatment modality in peripheral atherosclerosis in which 
much higher restenosis rates are observed compared with stenting in coronary arteries.98-101 
Stenting implies endovascular placement of a metal scaffold that eliminates elastic recoil 
and negative remodeling, thereby preserving the vascular lumen.102 The accumulating 
number of reports of reduced restenosis rate after stenting (compared with PTCA)93,103 led 
to widespread agreement of coronary stenting as the therapy of first choice for coronary 
atherosclerosis.92,104,105 Although results of PTCA have improved substantially over the past 
decade106 and stenting significantly reduced angiographic restenosis in comparison with 
PTCA,93,103,107 development of ISR still remains an unsolved clinical problem occurring in 
15%-30% of stented arteries.108-111 ISR can be diagnosed both clinically and angiographically. 
Clinically, ISR after coronary stenting is defined as the presence of recurrent angina or 
evidence of myocardial ischemia.112 Angiographically, ISR  is considered to be present if 
lumen diameter loss is > 50%.94,112
Risk factors for ISR
Risk factors for ISR are summarized in Table 1. The predictors of ISR are various in nature, 
and are related to both patient-dependent factors, and lesion- and procedure-dependent 
factors. In particular diabetes mellitus (DM) is considered as a major risk factor for 
restenosis after both bare-metal and drug-eluting stenting.113-120 In a retrospective study by 
Abizaid et al. the restenosis rate was 16.3% for patients without diabetes, 17.6% for patients 
with Type 2 diabetes, and 28% for patients with Type 1 diabetes.121 In a meta-analysis of 
six studies including a total number of 1166 patients with diabetes (predominantly Type 
2 diabetes) and 5070 non-diabetics, Gilbert et al. reported an average restenosis rate of 
36.7% and 25.9% in diabetics and non-diabetics, respectively.122 In this study, restenosis 
rates were also shown to correlate with age. After stratification for age, the authors 
demonstrated that the diabetic patients were older and that the incidence of restenosis 
after stenting was reduced approximately 50% after adjusting for age which led to the 
conclusion that the apparent effect of diabetes on restenosis might be overstated.122 West 
et al. retrospectively analyzed all stented diabetic patients in 16 studies of percutaneous 
coronary interventions.123 Within these studies, 418 of 3090 (14%) of the stented patients 
with 6-month angiographic follow-up had DM. Restenosis occurred in 21% of the non-DM 
and 31% of the DM patients, with no significant difference in age between the two groups. 
Loutfi et al. suggested that an important contributor to the increased need for repeated 
revascularization intervention among diabetics is not only restenosis but also progression 
of coronary atherosclerotic disease.124 Therefore, it appears reasonable to assume from the 
numerous studies conducted, that DM indeed predisposes for ISR although the magnitude 
of this effect of diabetes is still inconclusive.91 
Individuals with DM usually present with signs of accelerated atherosclerosis (i.e. 




with silent myocardial ischemia, peripheral artery disease, and stroke.125 The exact 
pathogenetic mechanism(s) underlying development of DM-associated macrovascular 
disease are as yet unknown. Macrovascular disease in DM has been shown to be associated 
with a decline in EPC number and function which might therefore contribute to diabetic 
vascular complications.126-129 Furthermore, the frequency of SMPCs was shown to be 
increased in subjects with Type 1 DM.130 The data suggest that, as a result from DM, 
the balance between EPCs and SMPCs might be disturbed in favor of the latter thereby 
resulting in enhanced atherosclerosis and restenosis rates. This suggest the existence of 
Table 1. Risk factors for the development of  in-stent restenosis after stenting




metabolic disorders diabetes mellitus 110,114,121,281
RAAS system higher plasma angiotensin-converting enzyme 
levels
116




BCHE, GPX1 and ROS1 283
endothelial nitric oxide synthase 284




systemic arterial hypertension 281
gender (female gender with a lower risk of 
restenosis after coronary stenting)
281,287
elevated C-reactive protein 288-290
recurrent restenosis 110
earlier neointimal response and the extent of 
neointimal proliferation predicted a high risk for 
target vessel revascularization
291







vessel /lesion lesion length (long lesions) 109,293
lesion location (left anterior descending artery, 
ostial lesion)
294,295
small vessel size 281,296
plaque morphology (soft plaque) 297,298
residual plaque burden 299
stent multiple stents 114,116
longer stent length and physical stent parameters 
(thinner struts elicits less angiographic and clinical 
restenosis)
111,300-303
procedure postprocedural lumen diameter (smaller final 
minimal lumen diameter immediately after 
stenting)
111,114,295




a causal relationship between the presence of DM, impeded capacity to restore vascular 
integrity, and the development of macrovascular disease.
Pathogenesis of ISR
ISR can be considered as a wound healing response97 as the cellular and molecular 
mechanisms involved in ISR have similarities with those involved in wound healing.112,131 
During wound healing, best characterized by the healing response to dermal injury, a 
thrombotic and acute inflammatory reaction is followed by the granulation tissue phase 
with macrophage infiltration, myofibroblast influx and angiogenesis.132 The events leading 
to ISR can be divided into two distinct phases based on the time of occurrence after 
stenting: the early phase (days to weeks) and the late phase (weeks to months).112 The early-
phase is characterized by endothelial damage caused by mechanical injury due to stent 
deployment followed by thrombotic events and inflammation.112,133 The late phase is mostly 
associated with neointimal hyperplasia.134 As shown by Farb et al. studying the course 
of the histopathological appearance of coronary arteries after stenting, early lesions are 
characterized by platelet-rich thrombus formation and an acute inflammatory response. In 
this early phase, neointima formation was absent in any of the patients with less than 11 
days post-stenting follow-up. However, in the late phase neointimal lesions were present 
in 45% and 100% of patients with a post-stenting follow-up of 12-30 days and >30 days, 
respectively.135 
In the development of ISR, neointima formation appears to precede reendothelialization. 
Early after stent deployment no ECs on the stented luminal surface are left. Even 6 weeks 
after stenting, the luminal border is not (fully) covered by ECs, and at this time neointimal 
VSMCs form the border between the neointima and the recirculating blood. Neointima 
formation starts with a reparative process characterized by coverage of the stented area 
by a thin, membranous thrombus with entrapped red blood cells, thrombocyte aggregates 
and polymorphonuclear leukocytes. Following acute endothelial denudation and platelet 
adhesion, in the absence of mature endothelium in the early phase, VSMCs accumulate 
and start to proliferate and secrete ECM components. Although 28 days after stenting some 
VSMCs can be detected in the developing neointima, after 12 weeks VSMCs form the main 
component of the neointima. Whereas reendothelialization is complete by 3 to 4 months, 
VSMC accumulation peaks around 9-18 months after stenting.131,136-138
There is an important relation between inflammation and ISR.139-142 Stent-induced 
damage of the atherosclerotic plaques as well as the arterial wall (characterized by fibrous cap 
rupture, stent strut penetration into the lipid core and deep arterial laceration) is associated 
with (chronic) inflammation which is in turn associated with enhanced neointimal 
growth.131,135,136,143,144 The stenting procedure itself forms a strong inflammatory stimulus, and 
ISR might therefore be regarded as a remodeling response to mechanical vascular damage 
induced by stent deployment.94 Initial damage to ECs leads to up-regulation of endothelial 
adhesion molecules that will induce leukocyte recruitment followed by transmigration into 
the intima upon chemotactic stimulation with proinflammatory cytokines.101 In addition 




response which is characterized by increased circulating levels of pro-inflammatory 
mediators such as IL-1, IL-6 and TNF-α.145 Following stenting, the accumulating platelets, 
leukocytes as well as the resident vascular wall cells (ECs and VSMCs) secrete cytokines and 
growth factors (e.g. PDGF, TGF-β, EGF) that in turn function as mitogens and chemotaxic 
agents for VSMCs and macrophages in a paracrine fashion4,112,146,147 thereby aggravating the 
development of ISR.
Origin of neointimal cells in ISR 
Alike TA, neointimal hyperplasia in ISR mainly consists of proliferating VSMCs136,148,149 
embedded in ECM.134-136,142,150,151 As already outlined above for the development of TA, 
development of ISR is classically attributed to migration, proliferation and apoptosis of 
medial VSMCs152 due to: 1) mechanical stretch, rupture of the internal elastic lamina, and 
medial dissection; 2) endothelial denudation with exposure to circulating mitogens such as 
angiotensin II and plasmin; and 3) release of mitogens and cytokines from platelets, ECs, 
medial VSMCs, and inflammatory cells.102
In line with the response-to-injury hypothesis proposed by Ross62 for the development 
of atherosclerosis, neointimal VSMCs may originate from the media of the stented 
vessels. After stenting, medial VSMCs loose their quiescent contractile state and enter 
cell cycle. Medial VSMCs also start to migrate through the internal elastic lamina into 
the subendothelial space of the intima, where they start to synthesize ECM components 
and contribute to neointima formation.136 According to this concept, medial VSMCs form 
a potential target for intervention by preventing dedifferentiation towards a synthetic 
phenotype characterized by migration, proliferation and ECM synthesis. In line with this, 
in vivo adenoviral delivery of A20 to medial VSMCs in rat carotid arteries was shown 
to attenuate medial VSMC proliferation and subsequent neointima formation following 
balloon angioplasty.153
However, as observed in TA accumulating evidence indicate a blood borne origin 
of neointimal cells also in different models of endovascular injury thereby raising the 
possibility that also sources other than the media (BM, circulation, peripheral tissues and 
vascular wall niches)  provide progenitors cells for neointimal VSMCs after stenting. It 
is as yet unknown if, and to what extent, these cells contribute to neointima formation 
in ISR. However, scarce data suggest the contribution of BM-derived cells to neointima 
formation in ISR as Hibbert et al. showed the presence of c-kit+ vascular progenitor cells 
in the neointima in human coronary ISR.154 Moreover, Skowasch et al. have shown the 
presence of BM- and neural-crest-derived cells in atherectomy samples retrieved from 
patients with ISR also suggesting recruitment of extravascular cells that contribute to 
neointima formation after stenting.23 
Transplant arteriosclerosis and in-stent restenosis: differences and similarities 
As outlined in the previous sections above, vascular remodeling in TA and ISR appear to share 




response to endovascular injury. Besides their aforementioned similarities (endothelial 
dysfunction, inflammation-driven, increased expression of EC adhesion molecules, and 
VSMC proliferation and migration), there are clear differences especially in the inciting events 
of vascular remodeling process as well as in the associated confounding factors that modulate 
their progression (Figure 2). Both the differential events as well as common pathways need to 
be considered when designing new therapeutic strategies to attenuate TA and ISR.  
The various characteristics of TA and ISR are summarized in Table 2 in which 
differences and similarities are indicated. Endothelial dysfunction is an early feature of 
vascular disease39 that contributes to the pathogenesis of both TA and ISR. Endothelial 
dysfunction reflects EC damage and is the first step in a cascade of pathological events 
that will end up in NI formation. Although the initial triggers of endothelial injury and 
dysfunction differ between TA and ISR (i.e. mechanical injury in ISR and transplantation-
related endothelial injury in TA [see Table 2 and Figure 2]), the subsequent events 
following endothelial activation like leukocyte infiltration appear to be highly similar 
between the two vasculopathies. Moreover, both ISR and TA have deleterious effects on 
systemic EC function.46,47,155,156 As endothelial dysfunction is a systemic disorder which 
is key in the pathogenesis of atherosclerosis and its complications39, strategies aiming at 
improving systemic EC function will also translate into reduced cardiovascular morbidity 
and mortality.157,158 Upon endothelial injury, (BM-derived) CD34+ EPCs participate in 
Table 2. Mechanisms and risk factors for TA and ISR: differences (red) and similarities (green)
Variable Transplant arteriosclerosis (TA) In-stent restenosis (ISR)
initiating injury immune response mechanical injury
time of development months  to years months  to years
localization diffuse focal
intimal proliferation concentric concentric
constrictive remodeling present absent
clinical manifestation insidious abrupt






EC damage, inflammation, thrombosis 
progenitor cell recruitment, VSMC 
migration and proliferation
EC damage, inflammation,  thrombosis, 
progenitor cell recruitment, VSMC 
migration and proliferation
risk factors Transplantation-dependent (acute 
rejection episodes, ischemia-
reperfusion, donor brain death, 
major histocompatibility mismatch) 
and -independent  (hyperlipidemia, 
diabetes, oxidative stress, hypertension, 
inflammation, elevated C-reactive 
protein, infections, environmental 
stimuli)
hyperlipidemia, diabetes, oxidative 
stress, hypertension, inflammation, 





reendothelialization.159-162 Circulating endothelial progenitor cells are able to participate 
in vascular repair by homing to the injured vascular wall and differentiation into ECs 
(i.e. reendothelialization). In addition to these presumably beneficial effects of EPCs 
facilitating endothelial repair, recirculating (BM-derived) SMPCs may actually promote 
the development of coronary artery disease and  restenosis.11,14,160,163,164
The inciting events leading to TA and ISR thus clearly differ (Table 2). Mismatched 
HLA-antigens on allografts act as chronic stimuli for ongoing inflammatory responses 
Figure 2. Pathobiology of transplant arteriosclerosis and in-stent restenosis. Although the initial triggers of 
endothelial injury and dysfunction differ between TA and ISR (i.e. mechanical injury in ISR and transplantation-
related endothelial injury in TA), the subsequent events following endothelial activation (like leukocyte 
infiltration, vascular progenitor cell recruitment and proliferation) appear to be highly similar between the two 
vasculopathies. Representative photomicrographs after Lawson-staining (elastin) showing (A) a non-injured 
rat aorta, (B) neointima hyperplasia in rat aortic allograft (i.e. TA), (C) neointima hyperplasia in stented rat 




(i.e. rejection) causing alloimmune-mediated damage to the vessel wall. After stenting, 
acute mechanical injury instead of rejection causes inflammation and results in chronic 
low-grade VSMC proliferation due to continuous presence of the stent.94 Transplantation-
related factors known to contribute to vascular injury in TA (e.g. acute rejection episodes, 
ischemia-reperfusion, donor brain death, HLA mismatch), are unique for allografted organs 
and are clearly absent in ISR. On the other hand there are also shared factors that play a role 
in both the development of TA and ISR such as hyperlipidemia, diabetes, oxidative stress, 
hypertension, cytokine modulation, inflammation, elevated C-reactive protein, infections, 
and other environmental stimuli such as smoking.91,165 
Diabetes and hyperlipidemia
Diabetes is considered a major risk factor for ISR. Similarly, data from both experimental 
models166 and clinical studies167 suggest an important role for metabolic abnormalities 
also in the pathophysiology of TA. Hypertriglyceridemia, hyperhomocysteinemia, 
hypertension, hyperglycemia, obesity, and insulin resistance occur with a high frequency 
in heart transplant patients.168,169 Hyperlipidemia is commonly seen in cardiac transplant 
patients and many of these patients were already hyperlipidemic even before they were 
transplanted. In addition, the immunosuppressive therapy given to transplant recipients 
(especially calcineurin inhibitors) may cause or exacerbate pre-existing dyslipidemia. This 
so-called metabolic syndrome is associated with endothelial dysfunction and atherosclerosis 
and development of occlusive vascular disease in the general population170 and in particular 
in diabetics and heart transplant recipients. 
Pre-existing atherosclerosis
Stenting is generally performed within a diseased artery with manifest atherosclerosis. 
Cardiac transplantation is performed using supposedly donor hearts non-affected by 
manifest atherosclerosis, although the endothelium might be damaged due to donor brain 
death and ischemia-reperfusion injury. Nevertheless, clinical studies also suggest a role of 
donor-transmitted, focal non-circumferential atherosclerotic plaques in the development 
of TA in heart transplant recipients.171 Although pre-existing donor lesions do not directly 
act as a starting point for the development of TA and do not affect survival of recipients, 
patients that received grafts with pre-existing atherosclerosis have a higher incidence of 
angiographic TA.172
VSMC proliferation and migration
Cytokine-induced activation of VSMCs is a critical cellular event in the development of 
both TA and ISR.91,173 The key stimuli for intimal hyperplasia that have been defined are 
injury, inflammation and increased mean wall stress, and these are all present in both TA 
and ISR and culminate in a final common pathway of VSMC proliferation and migration.4 
Although luminal narrowing is concentric both in TA and ISR (Figure 2 & 3), there 
are differences with regard to the extent of the lesions and their location. In TA neointima 




affected in cardiac transplantation. Conversely, in ISR the neointima is focal, and present 
at the stented region only. However, in contrast to circumferential neointima formation, 
which is more common in smaller arterial segments in TA, also focal plaque formation 
might appear in larger coronary arteries.171  Also after stenting concentric narrowing of the 
lumen is usually observed, although a more focal neointimal thickening can be observed 
which is associated with increased intramural bleeding.136 Constrictive remodeling has been 
described in TA.174-176 Although in ISR constrictive remodeling has a minimal importance 
due to the presence of the wire stent, there is a gradual reduction in neointima between 6 
months and 3 years,177 suggesting that the neointima itself can remodel over time.94
Kinetics of TA and ISR development
Difference between ISR and TA can also be observed regarding the kinetics of progression 
and severity. TA generally manifests after the first year post-transplantation with insidious 
clinical features culminating in graft failure eventually. ISR is characterized by an abrupt 
onset and rapid progression with intense proliferative activity followed by either stabilization 
or sudden appearance of a brutal ischemic event requiring urgent surgical intervention 
to restore perfusion. However, use of intravascular ultrasound (IVUS) revealed abnormal 
intimal thickening in 50% of transplant recipients already at 1 year post transplantation.178 
Figure 3. Neointima formation is the pathological hallmark of transplant arteriosclerosis and in-stent 
restenosis. This figure schematically displays arterial cross-sections of a healthy artery and arteries with transplant 
arteriosclerosis and in-stent restenosis. Upon vascular injury (alloreactivity against graft in transplantation and 
mechanical injury caused by stent struts) recruitment, homing and proliferation of vascular smooth muscle cells 




Stenting is demonstrated to have a triphasic luminal response179: the early restenosis phase 
(until 6 months) and the intermediate-term regression phase (from 6 months to 3 years) 
are followed by a late renarrowing phase beyond 4 years, when progressive increase in the 
incidence of late target lesion revascularization was observed up to 15 to 20 years after bare 
metal stent implantation.180 
Therapeutic perspectives to attenuate TA and ISR
Therapeutic strategies to attenuate TA
Although the use of improved immunosuppressive agents has resulted in adequate 
prevention and treatment of acute rejection181,182, adequate curative or preventive treatment 
of the development of TA is still lacking thereby remaining retransplantation as the only 
effective therapy. Besides efforts to optimize immunosuppressive therapy, attention has 
been directed towards disease prevention via attenuation of adverse non-immunologic and 
immunologic reactions.41,181,183,184 Once TA is established, pharmacological treatment options 
are limited and non-pharmacologic interventions are preferred.181 Fibrofatty plaques and 
focal coronary lesions are also displayed in TA185 which may be suitable for percutaneous 
coronary intervention and occasionally coronary bypass surgery. Therefore, stenting is 
a palliative cardiac interventional procedure applied both in native atherosclerosis and 
in TA, although interventions for revascularization in transplanted organs usually have 
disappointing short- and medium-term outcomes.186-188
Maintaining endothelial integrity and inhibiting VSMC proliferation represent two 
major goals in controlling NI formation. As EC injury is the first and most important trigger 
of TA development after cardiac transplantation189, rapid recovery from graft EC loss is 
key in preventing further graft EC injury and TA. The extent of endothelial cell apoptosis 
was directly correlated with the subsequent fibroproliferative changes.190-192 Moreover, 
the magnitude of EC chimerism was associated with vascular rejection thereby reflecting 
more aggressive alloreactivity against graft endothelium.193 Therefore, besides enhancing 
reendothelialization, preserving the graft endothelium seems to be a more rational 
approach to limit NI formation. Various (experimental) therapeutic approaches have been 
applied to improve EC function and reduce activation following transplantation194 as well 
as to enhance reendothelialization of mechanically injured vessels.195 These EC-directed 
therapies include mobilization of EPCs by pharmacologic treatment with e.g. statins196, 
cytokine-induced mobilization of hematopoietic precursor cells197, cell transfer of EPCs 
that are obtained from different sources198-200, overexpression of endothelial nitric oxide 
synthase (eNOS) in EPCs201, drug-eluting stents coated with an integrin-binding cyclic 
Arg-Gyl-Asp peptide or an antibody against CD34 which were able to capture circulating 
EPCs.202,203 
Several drugs other than statins are able to increase the number and functional 
activity of EPCs including peroxisome-proliferator activated receptor-γ (PPARγ) agonists 
(thiazolidinediones), angiotensin-converting enzyme (ACE) inhibitors, angiotensin II 




therapeutically enhanced, reduced NI formation as well as improved vascular wall function 
were commonly observed after endovascular injury (reviewed in 162,195). These observations 
clearly indicate that in restenosis, therapeutically enhanced reendothelialization is indeed 
beneficial. However, whether the same holds true for the development of TA still remains 
to be elucidated. In the view of therapeutic strategies, one should at least take into account 
one major difference between the development of TA and restenosis, i.e. the duration of the 
damage-inducing insults. In restenosis, there is only one major insult that induces damage 
that needs to be repaired (balloon inflation and the stenting procedure) with a persistent 
peri-strut chronic inflammatory response due to a foreign-body inflammatory reaction 
to the metal struts207, whereas after allografting, the intragraft vasculature is continuously 
exposed to damage-inducing factors due to ongoing subclinical rejection.
Caution is however warranted as, in contrast to some positive effects on 
reendothelialization, other data suggest that EPCs may actually promote TA rather than 
having a favorable effect on neointima development. After allogeneic aorta transplantation 
in BM-chimeric mice with Tie2-LacZ BM (mice expressing β-galactosidase in ECs) Hu 
et al. observed vasculogenesis within the neointimal lesions characterized by microvessel 
formation consisting of BM-derived ECs. Neointimal vasculogenesis developed in addition 
to neointimal EC replacement with non-BM-derived ECs.208 Microvessels appeared in 
allografts even before the onset of neointimal formation, suggesting that vasculogenesis 
within the intima may be a crucial event for the development of TA. If this dual role of 
circulating endothelial cells in the development of TA holds true, future strategies should 
on the one hand aim at enhancing reendothelialization with non-BM-derived circulating 
ECs, and on the other hand impair EPC-mediated vasculogenesis within the intima. In 
addition to neointimal vasculogenesis, neovascularization in the adventitia was shown to 
be responsible for promotion of intimal thickening209 and a correlation between adventitial 
neovascularization and aortic plaque progression in apolipoprotein E-deficient mice was 
shown.210 Inhibition of new vasa vasorum formation in the adventitia in response to injury 
might reduce circulating vascular progenitor cell recruitment. Moreover, a bipotential 
differentiation capacity of BM- and periphery-derived angiogenic progenitor cells has been 
demonstrated i.e. the capacity to differentiate into both EC and VSMC lineages.83 Therefore, 
therapeutic manipulation to skew differentiation of a common angiogenic ancestral 
progenitor cell towards the endothelial lineage may attenuate restenosis after angioplasty.83 
Further studies are required in order to determine which factors actually drive angiogenic 
progenitor cell differentiation towards the EC and VSMC lineage.
In addition to ECs, VSMCs are the major players in NI development and therefore 
their recruitment, migration and proliferation form potential targets for therapeutic 
intervention. Some of the currently used immunosuppressive drugs (including rapamycin, 
mycophenolic acid, cyclosporin, calcium channel blockers, and statins) have been shown to 
possess anti-proliferative effects on VSMCs.61 Proliferation signal inhibitors like sirolimus 
and its derivative everolimus were indeed associated with lower rates of acute rejection and 
reduced development of TA.211,212 Moreover, experimental interventions to modulate cell 




have been used to modulate the molecular programs that underlie medial VSMC migration 
and proliferation. However, strategies as such have not been demonstrably able to abolish 
TA development. The therapeutic measures might have higher efficacy when they target 
the SMPCs before their homing and proliferation is mounted, thereby interfering in early 
events. Modalities to influence their mobilization, recruitment, homing, and differentiation 
might represent efficacious strategies to limit NI formation. Cytokines and chemokines 
that have been shown to be important in these steps include granulocyte colony stimulating 
factor (G-CSF), stromal derived factor-1α (SDF-1α), c-kit and c-kit ligand (KitL, also 
known as stem cell factor or SCF), matrix metalloproteinase-9 (MMP-9), and vascular 
endothelial growth factor (VEGF) and its receptor.161 Among them, the SDF-1α/CXCR4 
axis has been reported to be involved in progenitor cell recruitment in numerous injury 
models including TA and its blockade resulted in decreased intimal hyperplasia.217-221
As current immunosuppressive regimens are still rather ineffective in preventing TA, 
other approaches will be needed. Instead of focusing only on eliminating the ‘weapon’ by 
debilitating the immune system, also protection of the target (the grafted organ) might 
help to control NI formation. In summary, several strategies can be identified, including 
1) preserving the endothelial lining and selectively increase EPC homing to promote 
reendothelialization, 2) blocking inflammatory and proliferative responses to impede 
VSMC migration and proliferation, and 3) limiting the recruitment and homing of SMPCs 
into the graft vessels. Future studies are needed in order to demonstrate whether approaches 
as such, in adjunct to current immunosuppressive protocols, are able to attenuate TA 
development.
Therapeutic strategies to attenuate ISR
The aforementioned potential strategies for limiting NI hyperplasia in TA by enhancing 
reendothelialization through EPC mobilization, recruitment and differentiation on the one 
hand, and inhibiting SMPC mobilization, recruitment, differentiation and proliferation on 
the other, is potentially valid also for prevention of ISR. Besides these common therapies 
of selective modulation of progenitor cell subsets and inhibiting VSMC proliferation, also 
some specific therapeutic approaches to target ISR can be identified. 
Development of ISR involves a cascade of traumatic, thrombotic, proliferative and late 
remodeling phases, culminating in the accumulation of VSMCs and matrix components 
in the NI eventually.151,222 Given the role of inflammation in ISR, research in vascular 
biology has focused on strategies to modulate the inflammatory process in the vessel wall. 
Various studies demonstrated that treatments that inhibited inflammation and reduced 
the expression of inflammatory cell adhesion molecules have beneficial effects on the 
development of ISR.223-225 For example, blockade of early monocyte recruitment resulted 
in reduced neointimal hyperplasia after stenting.223,224,226 Furthermore, clinical studies have 
shown reduced ISR with sirolimus- and paclitaxel-coated stents; agents with both anti-
proliferative and anti-inflammatory effects.227-229 Also PPARγ agonists (thiazolidinediones), 
which are known to have anti-inflammatory properties230, have been shown to attenuate 




Alike TA development, the presence of intact endothelium in mechanically injured 
arteries suppresses neointimal hyperplasia.196,198-200 The status of the vascular wall, and 
especially the vascular endothelium, is the key component of the response to vascular 
injury.235 Stenting damages the endothelium thereby resulting in endothelial dysfunction 
which is the result of an imbalance between vasodilator substances with anti-proliferative 
properties (such as NO), and vasoconstrictors with mitogenic properties (such as 
endothelin).39 Patti et al. showed that impaired flow-mediated dilation of the brachial 
artery independently predicts occurrence of coronary ISR.236 The systemic and local milieu 
associated with endothelial dysfunction favors cell proliferation, intimal hyperplasia, and 
vasoconstriction, which may all contribute to the development of restenosis. Indeed, local 
release of endothelin-1 at the site of vascular injury has been observed237, and treatment 
with an endothelin receptor antagonist attenuates ISR.238 Moreover, the administration 
of L-arginine, the precursor of nitric oxide (NO), inhibits lesion formation after balloon 
injury239 and improves coronary EC function.240 The recovery of the vascular endothelium 
and the restoration of EC function early after revascularization are important therapeutic 
targets for the prevention of restenosis and associated clinical events.235 Stented arteries 
with intact endothelium favors for a faster reendothelialization and less intimal thickening 
compared with previously denuded stented arteries.241 Moreover, perivascular implantation 
of tissue-engineered ECs around injured arteries has been shown to reduce neointimal 
thickening in bovine and porcine models of carotid arterial injury, thereby underscoring 
the critical role of ECs in the regulation of vascular function and vascular remodeling.242,243 
Many of the protective actions of the endothelium is mediated by NO which was shown 
to inhibit VSMC migration and proliferation.244 In line with this, NO-eluting stents are 
able to significantly reduce ISR in rabbits.245 Moreover, local gene transfer of inducible 
nitric oxide synthase (iNOS) was shown to reduce NI formation in pigs.246,247 Therefore, 
increasing bioavailability of NO and NOS might represent potential therapeutic approaches 
to control vascular healing. Besides local interventions, therapies with drugs that improve 
EC function (such as ACE inhibitors, statins, and antioxidants) have been shown to reduce 
the risk of restenosis in patients with EC dysfunction.39,45,158,236
The two major complications associated with stenting are stent thrombosis and 
restenosis.91 Initially, thrombotic events were responsible for the high rate of loss of stent 
patency early after stenting. However, changes in antiplatelet therapy248 and improvement 
of stent implantation techniques have significantly decreased the incidence of fatal stent 
thrombosis to less than 1%.222 Although the thrombotic process can be almost entirely 
prevented, its inhibition does not ensure long-term vessel patency222 as stenting still results 
in a relatively high restenosis rate.
Table 3 summarizes the various therapeutic approaches that have been tested for their 
efficacy in reducing restenosis, including mechanical angioplasty devices (reviewed in 
91,101,249), brachytherapy (intracoronary radiation)250-252, gene therapy246,247,253-255, local256-260 and 
systemic101,261-263 drug therapy, and the use of drug-eluting stents.202,227-229,252,264-270 Among these 
treatments, especially intravascular brachytherapy and the use of rapamycin- or paclitaxel-




Table 3. Pharmacological and cellular therapies to prevent restenosis
Type of intervention Reported interventions References
mechanical angioplasty 
devices to remove 
neointima
percutaneous transluminal coronary angioplasty, directional coronary 
atherectomy, high speed rotational atherectomy, cutting ballon
reviewed in 
91,101,249
brachytherapy intra-luminal radiation results in a lower rate of ISR 250-252
gene therapy gene-delivery of anti-MCP-1 gene reduced ISR in rabbits and monkeys 254
acceleration of reendothelialization via VEGF-2 gene-eluting stents 
inhibits neointimal proliferation in a hypercholesterolemic rabbit iliac 
angioplasty model
304
inducible nitric oxide synthase gene transfer was shown to reduce NI 
formation in pigs
246,247
local drug therapy paclitaxel delivered into the adventitia of pig femoral arteries 
effectively attenuates neointima after angioplasty
257
treatment of coronary ISR with paclitaxel-coated balloon catheters in 
humans reduced the incidence of restenosis
256,258-260
systemic drug therapy antithrombotic reviewed in 
101,261
antiinflammatory, antiproliferative: oral adjunctive sirolimus 
treatment after stent implantation results in significant improvement 
in the angiographic and clinical parameters of restenosis
262,263
peroxisome proliferator-activated receptor gamma agonists 231,305,306






(capture circulating EPCs): stents coated with an integrin-binding 
cyclic Arg-Gly-Asp peptide in porcine coronary arteries, stents coated 
with an antibody against CD34 in humans
202,203
increasing nitric oxide bioavailability (NO eluting stents significantly 
reduce ISR in rabbits)
245
results in a 50% reduction in restenosis and clinical events compared with repeated balloon 
angioplasty but features late thrombosis.250,251 Drug-eluting stents have reduced angiographic 
restenosis rates by ≥75% compared with bare-metal stents.271,272 Nonetheless, drug-eluting 
stents still do not completely solve the problem of ISR as the antiproliferative drug induces a 
cytostatic or cytotoxic effect on the neointimal vascular tissue which also impedes the natural 
healing response by delaying the formation of a functional endothelial layer covering the 
stent. Therefore, drug eluting stents hamper the reendothelialization process as compared 
with bare metal stents, which correlates with late stent thrombosis.137,273-275 An inhibiting 
effect of sirolimus on circulating vascular progenitor cells, leading to inhibition of NI 
formation, but also to a retarded reendothelialization was demonstrated.276 This observation 
supports the idea that sirolimus might interfere with vascular healing response. It seems that 
the prevention of one iatrogenic disease (ISR) produces another iatrogenic disease (late stent 




Although systemic or local delivery of anti-proliferative drugs like rapamycin or 
paclitaxel reduces ISR in humans258,262,263, development of ISR was not completely prevented. 
Therefore, a treatment strategy solely based on anti-proliferative actions may not be 
sufficient to completely block development of ISR. Cell migration rather than proliferation 
was shown to contribute to NI formation in the early phase after stenting. This stresses the 
importance of early therapeutic intervention with especially anti-migratory compounds 
after stenting279, and targeting of recruitment signals like the SDF-1α/CXCR4 axis and the 
SCF/c-kit pathway.221,280 The multifactorial nature of the response-to-injury argues against 
manipulation of a single biological process. Treatments to prevent ISR would ideally 
consists of a combinatorial approach using agents that reduce thrombosis and inflammation 
and enhance reendothelialization (by modulating angiogenic progenitor cell recruitment 
and differentiation), inhibit medial VSMC migration and neointimal cell proliferation by 
targeting multiple cell cycle check points and reduce ECM synthesis.277
Prevention of neointimal hyperplasia appears to require a multibranched approach 
and therapies aiming at reducing NI formation should interfere at different levels in 
the arteriosclerotic process, as one magic “bullet” that blocks all pathological events 
contributing to ISR is unlikely to exist.
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